Last reviewed · How we verify
NCT06101888
Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)
NA trial testing TaurusTrio™ Heart Valve System in Aortic Regurgitation in 116 participants. Currently enrolling.
31 July 2024
Quick facts
| Lead sponsor | Peijia Medical Technology (Suzhou) Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 116 |
| Start date | 1 August 2023 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2029 |
| Sites | 19 locations across China |
Drugs / interventions tested
- TaurusTrio™ Heart Valve System
Conditions studied
- Aortic Regurgitation — all drugs for Aortic Regurgitation →
Sponsor
Peijia Medical Technology (Suzhou) Co., Ltd.
Who can join
18 and older, any sex, with Aortic Regurgitation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and effectiveness of the TaurusTrio™ Heart Valve System in a patient population with symptomatic severe AR requiring replacement/repair of their native aortic valve that are at high risk for open surgical aortic valve replacement/repair (SAVR).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06101888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Regurgitation
Currently open trials in the same condition.
- NCT07197736 — DELINEATE-Prospective · recruiting
- NCT06818084 — TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System · Phase 4 · recruiting
- NCT06780241 — Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease · recruiting
- NCT06034028 — J-Valve TF Early Feasibility Study · NA · active not recruiting
- NCT04126018 — Comparative Imaging Assessment of Valvular Heart Disease · recruiting
Other Peijia Medical Technology (Suzhou) Co., Ltd. trials
Trials by the same sponsor.
- NCT05655897 — Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or · NA · recruiting
- NCT05610566 — Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or S · NA · recruiting
- NCT04744857 — Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve Replacement System With Retrievable Delivery Catheter Syste · NA · completed
- NCT04815785 — Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06101888 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peijia Medical Technology (Suzhou) Co., Ltd.
- Last refreshed: 18 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06101888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing